Background There is no effective therapy for the severe acute respiratory syndrome by
coronavirus 2 (SARS-CoV2) responsible for the Coronavirus disease 2019 (Covid-19). To …

Background Low-dose dexamethasone demonstrated clinical improvement in patients with
coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the …

As observed at the beginning of other coronaviruses epidemics, such as SARS in 2002 and
MERS in 2012 [1], the search of therapeutic interventions has been intense for the …

Objective To determine whether high-dose dexamethasone increases the number of
ventilator-free days (VFD) among patients with acute respiratory distress syndrome (ARDS) …

Objective The preferred agent of glucocorticoids in the treatment of patients with severe
COVID-19 is still controversial. This study aimed to compare the efficacy and safety of …

Importance Limited effective therapeutics are available to hospitalized patients with COVID-
19. Clinical trials and observational studies have shown varying effects of systemic …

Objectives: The question remained if mortality benefits with dexamethasone seen in patients
with coronavirus disease 2019 (COVID-19) also extend to other systemic corticosteroids …

Dexamethasone provides benefits in patients with coronavirus disease 2019 (COVID-19),
although data regarding immunological profiles and viral clearance are limited. This study …

The impressive results of the RECOVERY trial established that a moderate dose of
dexamethasone (6 mg daily for 10 days) reduced mortality in hospitalised patients with …

Background: The first case of Infection with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) were diagnosed in Wuhan, China in 2019. In the first half of 2020 this …